Abstract:
:Alzheimer's disease (AD) is the most prevalent dementia in the world. Its cause(s) are presently largely unknown. The most common explanation for AD, now, is the amyloid cascade hypothesis, which states that the cause of AD is senile plaque formation by the amyloid β peptide, and the formation of neurofibrillary tangles by hyperphosphorylated tau. A second, burgeoning theory by which to explain AD is based on the infection hypothesis. Much experimental and epidemiological data support the involvement of infections in the development of dementia. According to this mechanism, the infection either directly or via microbial virulence factors precedes the formation of amyloid β plaques. The amyloid β peptide, possessing antimicrobial properties, may be beneficial at an early stage of AD, but becomes detrimental with the progression of the disease, concomitantly with alterations to the innate immune system at both the peripheral and central levels. Infection results in neuroinflammation, leading to, and sustained by, systemic inflammation, causing eventual neurodegeneration, and the senescence of the immune cells. The sources of AD-involved microbes are various body microbiome communities from the gut, mouth, nose, and skin. The infection hypothesis of AD opens a vista to new therapeutic approaches, either by treating the infection itself or modulating the immune system, its senescence, or the body's metabolism, either separately, in parallel, or in a multi-step way.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Fülöp T,Munawara U,Larbi A,Desroches M,Rodrigues S,Catanzaro M,Guidolin A,Khalil A,Bernier F,Barron AE,Hirokawa K,Beauregard PB,Dumoulin D,Bellenger JP,Witkowski JM,Frost Edoi
10.1007/s40263-020-00737-1subject
Has Abstractpub_date
2020-07-01 00:00:00pages
673-695issue
7eissn
1172-7047issn
1179-1934pii
10.1007/s40263-020-00737-1journal_volume
34pub_type
杂志文章相关文献
CNS DRUGS文献大全abstract::New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418140-00005
更新日期:2004-01-01 00:00:00
abstract::Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients wit...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11587860-000000000-00000
更新日期:2011-07-01 00:00:00
abstract::Evidence-based treatment approaches for generalized anxiety disorder (GAD) comprise psychotherapy, pharmacotherapy, or a combination of the two. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, and, in certain European guidelines...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-014-0162-6
更新日期:2014-06-01 00:00:00
abstract::NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...
journal_title:CNS drugs
pub_type: 已发布勘误
doi:10.1007/s40263-018-0595-4
更新日期:2019-01-01 00:00:00
abstract::Diclofenac potassium powder for oral solution (Voltfast(®), Catafast(®), Cambia(®); hereafter referred to as diclofenac potassium powder) is a non-steroidal anti-inflammatory drug (NSAID), and is indicated for the acute treatment of migraine. This article reviews the pharmacological properties of diclofenac potassium ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-014-0186-y
更新日期:2014-08-01 00:00:00
abstract::Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200923060-00006
更新日期:2009-01-01 00:00:00
abstract::Numerous in vitro and in vivo experimental animal studies have demonstrated that gangliosides, particularly GMI ganglioside (siagoside), may stimulate or accelerate the repair of peripheral and central nervous system neurons after various types of damage. Clinical studies of GMl in peripheral neuropathies and stroke, ...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-199401030-00006
更新日期:1994-03-01 00:00:00
abstract::How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological fac...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0288-1
更新日期:2015-11-01 00:00:00
abstract:OBJECTIVE:To collect descriptive data on the treatment of Alzheimer's disease with galantamine under naturalistic conditions. STUDY DESIGN:This was a prospective, open-label, observational study. PATIENTS:Subjects (n = 345) with mild to moderately severe dementia of the Alzheimer's type were recruited from 48 hospita...
journal_title:CNS drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00023210-200620110-00006
更新日期:2006-01-01 00:00:00
abstract::Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adj...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0123-5
更新日期:2013-12-01 00:00:00
abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizu...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11208340-000000000-00000
更新日期:2011-10-01 00:00:00
abstract::Duloxetine (Cymbalta) is an orally administered, selective serotonin and noradrenaline reuptake inhibitor (SNRI) that has been approved for the treatment of major depressive disorder (MDD). Based on a considerable body of evidence, duloxetine at dosages ranging from 40 to 120 mg/day was effective in the short- and lon...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200721070-00004
更新日期:2007-01-01 00:00:00
abstract::Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depr...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-199809040-00003
更新日期:1998-04-01 00:00:00
abstract::Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00766-w
更新日期:2020-11-01 00:00:00
abstract:BACKGROUND:Few studies examine predictors of seizures in medically treated patients with epilepsy receiving antiepileptic monotherapy using a large patient population. OBJECTIVE:Our objective was to identify clinical, medication, and demographic factors associated with seizure recurrence in medically treated patients ...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-014-0191-1
更新日期:2014-11-01 00:00:00
abstract:BACKGROUND:Refractory status epilepticus (RSE) is an emergency with high mortality requiring neurointensive care. Treatment paradigms include first-generation antiepileptic drugs (AEDs) and anesthetics. Lacosamide (LCM) is a new AED, holding promise as a potent treatment option for RSE. High-level evidence regarding sa...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-013-0049-y
更新日期:2013-04-01 00:00:00
abstract::Satisfactory management of Parkinson's disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may experience motor complications despite optimized pharmacological therapy. Apomorphine, a short-acting D1- and D2-like receptor agonist, is the only dru...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-019-00661-z
更新日期:2019-09-01 00:00:00
abstract::The original article can be found online. ...
journal_title:CNS drugs
pub_type: 杂志文章,已发布勘误
doi:10.1007/s40263-018-0561-1
更新日期:2018-09-01 00:00:00
abstract::Alzheimer's disease (AD) is frequently associated with neuropsychiatric symptoms (NPS) such as agitation and aggression, especially in the moderate to severe stages of the illness. The limited efficacy and high-risk profiles of current pharmacotherapies for the management of agitation and aggression in AD have driven ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0270-y
更新日期:2015-08-01 00:00:00
abstract::Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health's (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the fai...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11530280-000000000-00000
更新日期:2010-02-01 00:00:00
abstract::Aripiprazole (Abilify(®)) is an atypical antipsychotic that is widely used in the treatment of psychiatric conditions. Unlike other currently available atypical antipsychotics that primarily have varying degrees of dopamine D2 receptor antagonism, aripiprazole is a partial agonist at D2 and serotonin 5-HT1A receptors,...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0134-2
更新日期:2014-02-01 00:00:00
abstract::The kynurenine pathway constitutes the main route of tryptophan degradation and generates the production of several neuroactive compounds; quinolinic acid is an excitotoxic NMDA receptor agonist, 3-hydroxykynurenine is a free-radical generator and kynurenic acid (KYNA) is an antagonist at glutamate and nicotinic recep...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200923020-00001
更新日期:2009-01-01 00:00:00
abstract::Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is pathologically characterized by inflammatory demyelination and neurodegeneration. Axonal damage, along with neuronal loss, occurs from disease onset and may lead to progressive and permanent disability. In contrast with the inflam...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0093-7
更新日期:2013-10-01 00:00:00
abstract::Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-012-0032-z
更新日期:2013-05-01 00:00:00
abstract:OBJECTIVE:This study examines the effects of parental lisdexamfetamine (LDX) treatment on parent-child interactions. METHODS:Participants were 30 parents (27% were male) and their children aged 5-12 years, both diagnosed with DSM-IV attention-deficit/hyperactivity disorder (ADHD). Optimal LDX dose (30, 50, or 70 mg/da...
journal_title:CNS drugs
pub_type: 杂志文章,随机对照试验
doi:10.1007/s40263-014-0165-3
更新日期:2014-07-01 00:00:00
abstract::As in all patient populations, epilepsy is common in pregnant women. Consequently, approximately 1 in 200 pregnancies is exposed to antiepileptic drugs (AEDs). Although exposure to AEDs in utero has been associated with an increased risk of major fetal malformations, most women with epilepsy require medication through...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200620100-00001
更新日期:2006-01-01 00:00:00
abstract::This review focuses on current information about luteal phase administration (i.e. typically for the last 2 weeks of the menstrual cycle) of pharmacological agents for the treatment of premenstrual dysphoric disorder (PMDD). Compared with continuous administration, a luteal phase administration regimen reduces the exp...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418070-00004
更新日期:2004-01-01 00:00:00
abstract::Disability, characterised by the loss of ability to perform activities of daily living (ADL), is a defining feature of dementia that results in growing caregiver burden and the eventual need for alternative care or nursing home placement. Functional decline in patients with dementia can also result from causes other t...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418130-00003
更新日期:2004-01-01 00:00:00
abstract:INTRODUCTION AND OBJECTIVE:Haemorrheological parameters and endothelial function are known to be altered in vascular diseases, including stroke. Treatment with HMG-CoA reductase inhibitors ('statins') improves cerebrovascular (and cardiovascular) morbidity and mortality in patients with atherosclerosis; the beneficial ...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-200418030-00003
更新日期:2004-01-01 00:00:00
abstract::Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first cli...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0299-y
更新日期:2016-01-01 00:00:00